Latest in News & Research
CDC Warns That Mpox Could Make a Summer Return
An outbreak in Chicago of the virus formerly called monkeypox has public health officials on edge
People With Alopecia Have Higher Risk for Inflammatory Arthritis
Increased risk seen for psoriatic and rheumatoid arthritis, and ankylosing spondylitis
Skin Lesions Often First Sign of Mpox Infection in 2022 Outbreak
39 percent of patients had fewer than five lesions; papules, vesicles, pustules predominated in first five days of infection
Dupilumab Beneficial for Adults With Prurigo Nodularis
All primary and key secondary end points met in two phase 3 trials of adults with PN with ≥20 nodules
Mindfulness, Self-Compassion Training Improves QOL in Eczema
Intervention group showed greater improvement in Dermatology Life Quality Index score at 13 weeks and in secondary end points
Electromagnetic Field Technology Plus Radiofrequency Cuts Visceral Adipose Tissue
High-intensity focused electromagnetic field technology with radiofrequency reduces VAT at three months; reduction maintained at six months
Adalimumab Plus Surgery Better for Hidradenitis Suppurativa
Greater reduction seen in International HS Severity Score System and in Dermatology Life Quality Index in combination group
Convolution Neural Network Aids Diagnosis for Melanocytic Lesions by Dermatologists
The most diagnostic improvement was seen for dermatologists with less dermoscopy experience cooperating with the CNN
CDC Reports No New Mpox Cases in Over a Week for First Time Since Outbreak Began
Since the outbreak began last May, more than 30,000 people have been infected with the virus and 42 people have died
New Model Helps ID Melanoma Patients With Lymph Node Involvement
Patient-centered methodology-generated probabilities better identify patients eligible for sentinel lymph node biopsy than those generated by conventional logistic regression analysis
Nearby Nature Does Not Protect Against Early Childhood Eczema
Exposure to coniferous, mixed forests and agriculture areas associated with elevated eczema risk
Child With Psoriasis Negatively Impacts Mom's Quality of Life
Positive association seen between mothers' Family Dermatology Life Quality Index scores and children's Psoriasis Area Severity Index scores
Good Agreement Found for Clinical, Photograph Assessment of Psoriasis
Intraclass correlation coefficient 0.78 between clinical and photographic Psoriasis Area and Severity Index
Anti-PD-1 More Effective With Normal Vitamin D Levels in Melanoma
Definition includes five domains of management of clinical symptoms, psychosocial elements, QoL, treatment, health care team support
Chronic Hand Eczema Rapidly Improves With Gusacitinib
Significant reductions seen over placebo for 80 mg gusacitinib in mTLSS, PGA, HECSI as early as week 2
Validity Demonstrated for Hidradenitis Suppurativa Investigator Global Assessment
Tool has good psychometric properties compared with existing measures
Is Model With SLN Status Effective in Predicting Melanoma-Specific Death?
Model estimating five-year MSD risk that includes sentinel lymph node status provides greater net benefits across treatment thresholds
Does Vitamin D Supplementation Impact Psoriasis Severity?
No difference seen in change in PASI score, Physician Global Assessment score, self-administered PASI, Dermatology Life Quality Index
Risk for Melanoma Reduced for Individuals With Atopy
Fewer cases of melanoma, lower investigator-estimated risk class of skin cancer observed in atopic versus nonatopic individuals
AAD: Long-Term Efficacy Seen for Baricitinib in Alopecia Areata
39.1 percent of baricitinib 4-mg-treated patients with SALT score >20 at week 52 achieved SALT score ≤20 by week 104
AAD: Nemolizumab Beneficial for Patients With Prurigo Nodularis
Improvement seen in primary and key secondary end points, including peak pruritus numerical rating scale, sleep disturbance
Promising Results Seen for Bimekizumab in Hidradenitis Suppurativa
Significantly higher proportion of hidradenitis suppurativa patients treated with bimekizumab achieved primary end point of HiSCR50
Long-Term Improvement Seen With Ruxolitinib in Vitiligo
Improvement in facial/total Vitiligo Area Scoring Index seen with continued treatment from weeks 52 to 104
24 of 1292